Celularity appoints Viome founder Naveen Jain to board of directors
Jain's seat, effective once a Rule 14f-1 waiting period ends, follows board designation rights tied to Celularity's September 2026 financing and comes as director Diane Parks resigns.
Celularity Inc. said on September 29, 2026 that its board had appointed Naveen Jain, founder and chief executive of Viome Life Sciences Inc., to serve as a director. The appointment was made by Celularity's board on September 29, 2026, with Jain's term to begin once the waiting period tied to a Section 14(f) information statement and Rule 14f-1 expires.1
Jain was designated for the board seat under board designation rights granted to certain investors in connection with Celularity's September 2026 financing, which the company had previously disclosed in a Form 8-K filed on September 28, 2026.1
The filing describes Jain's background: he is founder and CEO of Viome Life Sciences Inc., a health technology company applying artificial intelligence and molecular data to personalized health and nutrition, and he previously founded InfoSpace, Intelius and TalentWise and is the founder of Moon Express.1
Celularity stated that there are no family relationships between Jain and any director or executive officer of the company, no other arrangements or understandings tied to his selection beyond the board designation rights, and he is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.1 Jain will take part in the company's standard non-employee director compensation arrangements, is expected to sign the standard indemnification agreement, and has not yet been placed on any board committee.1
Alongside the appointment, director Diane Parks notified the company of her decision to resign from the board effective at the same time Jain's term begins, a move the filing said was not related to any disagreement over company operations, policies or practices.1
The filing also noted that Jain joins a newly constituted board alongside Robert Hariri, Peter Diamandis and Philip Barach, who recently joined as part of Celularity's broader recapitalization, with a fifth director expected to be named shortly.1 Celularity's therapy portfolio includes cenplacel-L, an investigational placenta-derived allogeneic cell therapy, among other investigational cellular therapies.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.